Bourgeon Capital Management’s TherapeuticsMD TXMD Stock Holding History

Bourgeon Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-200	Closed	-$64K	–	97
2016 Q1	$64K	Buy	+200	New	+$68.2K	0.04%	90

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bourgeon Capital Management's TXMD Position: Q2 2016 in Review

Bourgeon Capital Management sold out of TherapeuticsMD (TXMD) in Q2 2016, closing a stake of 200 shares — an estimated $64K sold.

Bourgeon Capital Management first reported a position in TXMD in Q1 2016 and held it in 1 quarter. The position peaked at $64K in Q1 2016. 123 funds tracked by Wall St. Rank hold TXMD as of Q2 2016.

Bourgeon Capital Management reported no remaining TherapeuticsMD position as of Q2 2016 after selling out during the quarter.
Bourgeon Capital Management sold 200 TherapeuticsMD shares in Q2 2016, an estimated $64K.
Bourgeon Capital Management first reported a position in TherapeuticsMD in Q1 2016 and held it in 1 quarter.
Bourgeon Capital Management's TherapeuticsMD position peaked at $64K in Q1 2016.
123 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2016.

Based on Bourgeon Capital Management's 13F filing for Q2 2016, filed 2 Aug 2016.